Company intelligence / Profile preview
Aurealis Pharma
Basel, Switzerlandaurealistherapeutics.com ↗
- Ownership
- Private
- Employees
- ~39
- Development stage
- Other
01
Overview
AUP-16 demonstrated positive Phase 2 results, tripling complete wound closure rate in chronic Diabetic Foot Ulcers; oncology program with AUP-55 showing impressive survival data in Ovarian Cancer.
- Therapeutic areas
- OncologyEndocrinologyDermatologyCardiovascular
- Modalities
- Cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aurealis Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurealis Pharma.